Literature DB >> 16703516

Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy.

Marisa Zanchetta1, Sarah Walker, Nicoletta Burighel, Domenico Bellanova, Osvalda Rampon, Carlo Giaquinto, Anita De Rossi.   

Abstract

To investigate the decay of the human immunodeficiency virus type 1 (HIV-1) reservoir in children receiving highly active antiretroviral therapy (HAART), we measured HIV-1 DNA in peripheral blood mononuclear cells from 14 children who achieved and maintained suppression of plasma viremia up to 48 months after the initiation of HAART. Levels of intracellular unspliced and multiply spliced HIV-1 RNA were used as markers of residual viral replication. During the first month of HAART, there were significant decays in levels of both plasma HIV-1 RNA and multiply spliced HIV-1 RNA, yet unspliced HIV-1 RNA persisted in most of the children. Greater HIV-1 DNA decay during the first month of HAART correlated with a higher concomitant increase in CD4(+) cell counts (P=.028) and a smaller subsequent HIV-1 DNA decay (P=.0012). Furthermore, HIV-1 DNA decayed faster from 1 to 9 months of HAART (median half-life, 5 months) than during the subsequent follow-up period (median half-life, 30 months). Moreover, after 9 months of HAART, HIV-1 DNA tended to decay more slowly in children with detectable levels of unspliced HIV-1 RNA. These findings suggest that clearance of the viral reservoir in HAART-treated children may be influenced by immune repopulation and residual viral replication and may help in refining long-term treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16703516     DOI: 10.1086/504264

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

2.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Authors:  Priyanka Uprety; Ellen G Chadwick; Kaitlin Rainwater-Lovett; Carrie Ziemniak; Katherine Luzuriaga; Edmund V Capparelli; Gayane Yenokyan; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2015-08-13       Impact factor: 9.079

3.  HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Authors:  Katherine Luzuriaga; Barbara Tabak; Manuel Garber; Ya Hui Chen; Carrie Ziemniak; Margaret M McManus; Danielle Murray; Matthew C Strain; Douglas D Richman; Tae-Wook Chun; Coleen K Cunningham; Deborah Persaud
Journal:  J Infect Dis       Date:  2014-05-21       Impact factor: 5.226

4.  Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children.

Authors:  Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo
Journal:  J Acquir Immune Defic Syndr       Date:  2018-10-01       Impact factor: 3.731

5.  Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failure.

Authors:  Paola Costenaro; Rebecca Lundin; Maria Raffaella Petrara; Martina Penazzato; William Massavon; Susan Kizito; Sandra Monica Nabachwa; Maria Nannyonga Musoke; Charles Namisi; Erika Morelli; Davide Bilardi; Antonio Mazza; Marisa Zanchetta; Carlo Giaquinto; Anita De Rossi
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

Review 6.  Very early combination antiretroviral therapy in infants: prospects for cure.

Authors:  Kaitlin Rainwater-Lovett; Katherine Luzuriaga; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

7.  Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus.

Authors:  Marta Massanella; Thanyawee Puthanakit; Louise Leyre; Thidarat Jupimai; Panadda Sawangsinth; Mark de Souza; Piyarat Suntarattiwong; Pope Kosalarksa; Thitiporn Borkird; Suparat Kanjanavanit; Kulkanya Chokephaibulkit; Rawiwan Hansudewechakul; Witaya Petdachai; Julie L Mitchell; Merlin L Robb; Lydie Trautmann; Jintanat Ananworanich; Nicolas Chomont
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

8.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.

Authors:  Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout
Journal:  JCI Insight       Date:  2020-03-26

9.  Treatment of pediatric HIV infection.

Authors:  Elisa A d'Oulx; Elena Chiappini; Maurizio de Martino; Pier-Angelo Tovo
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

10.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.